MWNA
IPSC icon

Marshall Wace North America’s Century Therapeutics IPSC Stock Holding History

Marshall Wace North America’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$14.4M Buy
571,053
+323,802
+131% +$8.76M 0.06% 292
2021
Q2 		$7.25M Buy
+247,251
New +$6.27M 0.03% 445

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's IPSC Position: Q3 2021 in Review

Marshall Wace North America increased its Century Therapeutics (IPSC) stake by 131% in Q3 2021, buying an estimated $8.76M and bringing the position to 571,053 shares worth $14.4M. The position accounts for 0.06% of the portfolio, ranked #292.

Marshall Wace North America first reported a position in IPSC in Q2 2021 and has held it in 2 quarters since. 49 funds tracked by Wall St. Rank hold IPSC as of Q3 2021.

  • Marshall Wace North America held 571,053 shares of Century Therapeutics worth $14.4M as of Q3 2021.
  • Marshall Wace North America bought 323,802 Century Therapeutics shares in Q3 2021, an estimated $8.76M.
  • Century Therapeutics made up 0.06% of Marshall Wace North America's portfolio in Q3 2021, its #292 holding.
  • Marshall Wace North America first reported a position in Century Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 49 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.